Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors

Trial Profile

Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Lurbinectedin (Primary) ; Olaparib (Primary)
  • Indications Breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms POLA
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2019.
    • 21 Jun 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2019.
    • 06 Jun 2017 Results (n=20) of phase I of the study assessing tolerability,pharmacokinetics and pharmacodynamics presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top